In a phase 3 trial, participants who received the shot were 29% less likely to be diagnosed with flu than those who received a conventional flu shot.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The 2024-25 season was the highest severity flu season in more than a decade, according to a new analysis of US surveillance data.
Test positivity is down slightly, but emergency department visits for COVID are elevated in children.
During the 2022-23 and 2024-25 flu seasons, the incidence of cardiorespiratory hospitalization was 2.25% in the high-dose group and 2.38% in the standard-dose group.
The vaccine, called OVX836, is designed to target the nucleoprotein (NP) of the influenza A virus, which is a highly conserved and less likely to mutate.
The CDC reported five more influenza-associated pediatric deaths, bringing the total for the 2024-25 flu season to 275.
When symptoms were described as lasting 2 days, only 31% of clinicians recommended treatment.
The CDC projects that COVID infections are growing or likely growing in most states.
The authors show how a relatively small serosurveillance scheme could complement traditional surveillance, enhancing epidemic understanding and forecast modeling.
The odds of a respiratory tract infection and any infection were lower in the SARS-CoV-2 group.
Notably, the dual therapy group had significantly lower 28-day mortality compared to their monotherapy peers and was associated with a shorter viral shedding time.
